> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vigil Neuro Ends Trial of Rare Brain Disorder Drug
- URL: https://www.fdaweb.com/vigil-neuro-ends-trial-of-rare-brain-disorder-drug/
- Published: 2025-06-04T12:00:00.000Z
- Updated: 2026-09-14T15:13:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159298

Vigil Neuroscience says it is discontinuing its Phase 2 long-term extension study of investigational therapy iluzanebart based on disappointing results in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

The company’s IGNITE trial, an open-label study evaluating two doses of iluzanebart, showed that the drug was safe and well-tolerated, but failed to demonstrate meaningful improvement on clinical or biomarker endpoints, the company says.

ALSP is described as a progressive, inherited brain disorder caused by mutations in the CSF1R gene. It typically strikes in midlife and leads to rapid cognitive decline, neuropsychiatric symptoms, and motor impairment, Vigil Neuroscience says, adding that life expectancy averages six to seven years after diagnosis.